|Articles|August 1, 2003

Bevacizumab Results Favorable But Not Definitive

Author(s)John Otrompke

Chicago - A phase II trial of a new recombinant agent in the fight against melanoma has accrued 28 patients so far, yielding interesting data but so far no conclusive results, according to an abstract presented at this year's annual meeting of the American Society of Clinical Oncology.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME